Versant Venture Management’s CRISPR Therapeutics CRSP Stock Holding History

Versant Venture Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.08M	Hold	148,831	–	–	5.01%	6
2025 Q4	$7.8M	Hold	148,831	–	–	5.17%	4
2025 Q3	$9.65M	Sell	148,831 -349,727	-70%	-$20.1M	4.54%	4
2025 Q2	$24.2M	Hold	498,558	–	–	29.52%	2
2025 Q1	$17M	Hold	498,558	–	–	28.18%	2
2024 Q4	$19.6M	Hold	498,558	–	–	22.62%	2
2024 Q3	$23.4M	Hold	498,558	–	–	36.84%	1
2024 Q2	$26.9M	Hold	498,558	–	–	34.84%	1
2024 Q1	$34M	Hold	498,558	–	–	32.95%	1
2023 Q4	$31.2M	Hold	498,558	–	–	8.03%	2
2023 Q3	$22.6M	Hold	498,558	–	–	12.03%	3
2023 Q2	$28M	Hold	498,558	–	–	33.2%	2
2023 Q1	$22.5M	Hold	498,558	–	–	47.01%	1
2022 Q4	$20.3M	Hold	498,558	–	–	41.93%	1
2022 Q3	$32.6M	Hold	498,558	–	–	55.55%	1
2022 Q2	$30.3M	Hold	498,558	–	–	46.45%	1
2022 Q1	$31.3M	Hold	498,558	–	–	31.24%	1
2021 Q4	$37.8M	Hold	498,558	–	–	20.21%	2
2021 Q3	$55.8M	Sell	498,558 -10,000	-2%	-$1.26M	23.11%	1
2021 Q2	$82.3M	Sell	508,558 -1,046,402	-67%	-$127M	27.28%	1
2021 Q1	$189M	Sell	1,554,960 -1,485,502	-49%	-$224M	36.92%	1
2020 Q4	$466M	Sell	3,040,462 -591,194	-16%	-$69.9M	48.34%	1
2020 Q3	$304M	Sell	3,631,656 -551,408	-13%	-$48.9M	55.59%	1
2020 Q2	$307M	Sell	4,183,064 -22,551	-0.5%	-$1.32M	44.16%	1
2020 Q1	$177M	Hold	4,205,615	–	–	48.6%	1
2019 Q4	$256M	Sell	4,205,615 -28,255	-0.7%	-$1.54M	77.19%	1
2019 Q3	$174M	Sell	4,233,870 -15,018	-0.4%	-$718K	67.15%	1
2019 Q2	$200M	Hold	4,248,888	–	–	58.31%	1
2019 Q1	$152M	Buy	4,248,888 +640,014	+18%	+$22.1M	50%	1
2018 Q4	$103M	Hold	3,608,874	–	–	51.04%	1
2018 Q3	$160M	Hold	3,608,874	–	–	54.44%	1
2018 Q2	$212M	Sell	3,608,874 -997,368	-22%	-$56.8M	66.16%	1
2018 Q1	$211M	Buy	+4,606,242	New	+$190M	67.34%	1

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Versant Venture Management's CRSP Position: Q1 2026 in Review

Versant Venture Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 148,831 shares worth $7.08M. The position accounts for 5.01% of the portfolio, ranked #6.

Versant Venture Management first reported a position in CRSP in Q1 2018 and has held it in 33 quarters since. The position peaked at $466M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Versant Venture Management held 148,831 shares of CRISPR Therapeutics worth $7.08M as of Q1 2026.
Versant Venture Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 5.01% of Versant Venture Management's portfolio in Q1 2026, its #6 holding.
Versant Venture Management first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 33 quarters since.
Versant Venture Management's CRISPR Therapeutics position peaked at $466M in Q4 2020.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.